Citius Pharmaceuticals Announces Results From The Phase 2b Study Of Halo-Lido For The Treatment Of Hemorrhoids
Portfolio Pulse from Benzinga Newsdesk
Citius Pharmaceuticals announced positive results from the Phase 2b study of Halo-Lido for hemorrhoid treatment, showing a significant reduction in symptom severity. The company has selected the dose for the Phase 3 trial and plans to schedule an end of Phase 2 meeting with the FDA.
June 20, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citius Pharmaceuticals' positive Phase 2b results for Halo-Lido may boost investor confidence and potentially lead to stock price appreciation.
The positive results from the Phase 2b study of Halo-Lido indicate that the treatment is effective in reducing hemorrhoid symptoms. This may increase investor confidence in the company's ability to successfully develop and commercialize the product, potentially leading to stock price appreciation in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100